雄激素受体可变剪接异变体7与前列腺癌关系的研究进展

doi:10.13481/j.1671-587x.20200533

摘要/Abstract

摘要： 雄激素受体（AR）信号通路在前列腺癌（PCa）发生发展过程中起重要作用。AR信号转导途径的改变和重新激活是促进去势抵抗性前列腺癌（CRPC）发展和耐药性产生的核心因素。AR可变剪接异变体7（AR-V7）的表达是AR信号通路异常激活的重要原因之一，AR-V7具有与AR不同的结构及功能，在PCa发展、耐药和临床治疗中起着重要的推动作用，同时也具有作为CRPC生物标志物和治疗靶标的巨大潜力。现总结分析AR与AR-V7的结构和功能上的差异，以及在AR靶向药物作用下CRPC患者的疗效，为CRPC的治疗提供理论依据。阐述AR-V7在PCa治疗和耐药方面的主要研究进展及其在判断CRPC疗效和预后方面的作用，同时进一步分析AR-V7特异性检测在临床应用中的不足之处，以期取得技术上的进步和发展。

关键词: 前列腺肿瘤, 去势抵抗性前列腺癌, 雄激素受体, 雄激素受体可变剪接异变体7, 多烯紫杉醇

中图分类号:

R737.25

于冰冰, 李扬, 邵晨. 雄激素受体可变剪接异变体7与前列腺癌关系的研究进展[J]. 吉林大学学报(医学版), 2020, 46(05): 1092-1098.

YU Bingbing, LI Yang, SHAO Chen. Research progress in relationship between androgen receptor splicing variant 7 and prostate cancer[J]. Journal of Jilin University(Medicine Edition), 2020, 46(05): 1092-1098.

参考文献

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2] CHEN W Q, ZHENG R S, ZENG H M, et al. The updated incidences and mortalities of major cancers in China, 2011[J]. Chin J Cancer, 2015, 34(3):1-6.
[3] NA R, YE D W, QI J, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL:Results from a Multicenter Study in China[J]. Prostate, 2017, 77(11):1221-1229.
[4] COSTEA T, NAGY P, GANEA C, et al. Molecular mechanisms and bioavailability of polyphenols in prostate cancer[J]. Int J Mol Sci, 2019, 20(5):1062.
[5] LOGOTHETIS C J, GALLICK G E, MAITY S N, et al. Molecular classification of prostate cancer progression:foundation for marker-driven treatment of prostate cancer[J]. Cancer Discov, 2013, 3(8):849-861.
[6] NEAD K T, GASKIN G, CHESTER C, et al. Association between androgen deprivation therapy and risk of dementia[J]. JAMA Oncol, 2017, 3(1):49-55.
[7] KARANTANOS T, CORN P G, THOMPSON T C. Prostate cancer progression after androgen deprivation therapy:mechanisms of castrate resistance and novel therapeutic approaches[J]. Oncogene, 2013, 32(49):5501-5511.
[8] COUTINHO I, DAY T K, TILLEY W D, et al. Androgen receptor signaling in castration-resistant prostate cancer:a lesson in persistence[J]. Endocr-Relat Cancer, 2016, 23(12):T179-T197.
[9] THELEN P, TAUBERT H, DUENSING S,et al. The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer[J]. Aktuelle Urol, 2018, 25:1-11
[10] MAUGHAN B L, ANTONARAKIS E S. Androgen pathway resistance in prostate cancer and therapeutic implications[J]. Expert Opin Pharmacother, 2015, 16(10):1521-1537.
[11] TAN M E, LI J, ERIC XU H, et al. Androgen receptor:structure, role in prostate cancer and drug discovery[J]. Acta Pharmacol Sin, 2015, 36(1):3-23.
[12] CICCARESE C, SANTONI M, BRUNELLI M, et al. AR-V7 and prostate cancer:The watershed for treatment selection?[J]. Cancer Treat Rev, 2016, 43:27-35.
[13] DE LAERE B, VAN DAM P J, WHITINGTON T, et al. Comprehensive profiling of the androgen receptor in liquid biopsies from castration-resistant prostate cancer reveals novel intra-AR structural variation and splice variant expression patterns[J]. Eur Urol, 2017, 72(2):192-200.
[14] THADANI-MULERO M, PORTELLA L, SUN S H, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer[J]. Cancer Res, 2014, 74(8):2270-2282.
[15] GUO Z Y, YANG X, SUN F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth[J]. Cancer Res, 2009, 69(6):2305-2313.
[16] CAO S B, ZHAN Y, DONG Y. Emerging data on androgen receptor splice variants in prostate cancer[J]. Endocr-Relat Cancer, 2016, 23(12):T199-T210.
[17] NAKAZAWA M, ANTONARAKIS E S, LUO J. Androgen receptor splice variants in the era of enzalutamide and abiraterone[J]. Horm Cancer, 2014, 5(5):265-273.
[18] SUN S H, SPRENGER C C T, VESSELLA R L, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant[J]. J Clin Investig, 2010, 120(8):2715-2730.
[19] TAGAWA S T, ANTONARAKIS E S, GJYREZI A, et al. Expression of AR-V7 and ARv^567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY[J]. Clin Cancer Res, 2019, 25(6):1880-1888.
[20] LIU X C, LEDET E, LI D Y, et al. A whole blood assay for AR-V7 and AR v567es in patients with prostate cancer[J]. J Urol, 2016, 196(6):1758-1763.
[21] CATO L, DE TRIBOLET-HARDY J, LEE I, et al. ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer[J]. Cancer Cell, 2019, 35(3):401-413.e6.
[22] HU R, LU C X, MOSTAGHEL E A, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer[J]. Cancer Res, 2012, 72(14):3457-3462.
[23] HAO Z L, ZHANG H, COWELL J. Ubiquitin-conjugating enzyme UBE2C:molecular biology, role in tumorigenesis, and potential as a biomarker[J]. Tumor Biol, 2012, 33(3):723-730.
[24] WANG Q B, LI W, ZHANG Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer[J]. Cell, 2009, 138(2):245-256.
[25] XUE Y N, YU B B, LIU Y N, et al. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis[J]. Prostate, 2019, 79(6):647-656.
[26] ZHU Q Q, MA C H, WANG Q, et al. The role of TWIST1 in epithelial-mesenchymal transition and cancers[J]. Tumor Biol, 2016, 37(1):185-197.
[27] CHEN L, CAO H W, FENG Y G. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1[J]. World J Urol, 2018, 36(3):357-365.
[28] CANEL M, SERRELS A, FRAME M C, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis[J]. J Cell Sci, 2013, 126(Pt 2):393-401.
[29] HWANG C. Overcoming docetaxel resistance in prostate cancer:a perspective review[J]. Ther Adv Med Oncol, 2012, 4(6):329-340.
[30] CHEN X, BERNEMANN C, TOLKACH Y, et al. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy[J]. Urol Oncol:Semin Orig Investig, 2018, 36(4):161.e19-161.e30.
[31] ZHU M L, HORBINSKI C M, GARZOTTO M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer[J]. Cancer Res, 2010, 70(20):7992-8002.
[32] XUE D, LU H, XU H Y, et al. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12[J]. J Cell Mol Med, 2018, 22(6):3223-3237.
[33] WARE K E, GARCIA-BLANCO M A, ARMSTRONG A J, et al. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer[J]. Endocr-Relat Cancer, 2014, 21(4):T87-T103.
[34] ZHAO K, ZHOU Y X, QIAO C, et al. Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells[J]. J Hematol Oncol, 2015, 8(1):1-18.
[35] FRANCINI E, PETRIOLI R, ROSSI G, et al. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer:an analysis of 22 trials[J]. Tumor Biol, 2014, 35(11):10601-10607.
[36] POLESSKAYA A, PINNA G, SASSI Y, et al. Post-transcriptional modulation of interleukin 8 by CNOT6L regulates skeletal muscle differentiation[J]. Biochim Biophys Acta BBA-Mol Cell Res, 2016, 1863(2):263-270.
[37] CHEN H W, LI H L, CHEN Q. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI₃K/Akt signaling pathway in prostate cancer[J]. Biochem Biophys Res Commun, 2016, 477(3):467-472.
[38] CHENG B, CRASTA K. Consequences of mitotic slippage for antimicrotubule drug therapy[J]. Endocr-Relat Cancer, 2017, 24(9):T97-T106.
[39] KOMURA K, JEONG S H, HINOHARA K, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression[J]. Proc Natl Acad Sci U S A, 2016, 113(22):6259-6264.
[40] MOHR L, CARCELES-CORDON M, WOO J, et al. Generation of prostate cancer cell models of resistance to the anti-mitotic agent docetaxel[J]. J Vis Exp, 2017(127):56327-56335.
[41] HUNTER I, HAY C W, ESSWEIN B, et al. Tissue control of androgen action:The ups and downs of androgen receptor expression[J]. Mol Cell Endocrinol, 2018, 465:27-35.
[42] SHEN M M, ABATE-SHEN C. Molecular genetics of prostate cancer:new prospects for old challenges[J]. Genes Dev, 2010, 24(18):1967-2000.
[43] UO T, PLYMATE S R, SPRENGER C C. The potential of AR-V7 as a therapeutic target[J]. Expert Opin Ther Targets, 2018, 22(3):201-216.
[44] WILSON S, CAVERO L, TONG D L, et al. Resveratrol enhances polyubiquitination-mediated ARV7 degradation in prostate cancer cells[J]. Oncotarget, 2017,8(33):54683-54693.